First Clinical Trial With Induced Pluripotent Stem Cells Grows Closer
By Dennis Normile,
Science
| 06. 26. 2013
A Japan Ministry of Health, Labour and Welfare panel has accepted a plan to carry out what would be the world's first clinical trials involving induced pluripotent stem (iPS) cells. The acceptance paves the way for an official green light from the ministry, which could come in early July.
Researchers at the RIKEN Center for Developmental Biology in Kobe plan to generate replacement retinal pigment epithelial cells from iPS cells generated from patients suffering age-related macular degeneration. The research has been under way for several years and was widely
reported at conferences.
Approval for clinical trials was expected to be routine. However, the health ministry panel cited safety concerns in putting off a decision in late May. Japanese media reported that the panel met again today and accepted additional data submitted by RIKEN. Formal approval will be up to the ministry. RIKEN could start recruiting patients sometime this year.
Related Articles
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...
By Anna Collinson, Maryam Ahmed and Bella McShane, BBC | 03.12.2024
Women who freeze their eggs are being misled by some UK clinics about their chances of having a baby, a fertility charity says.
The Fertility Network was reacting to BBC analysis that found 41% of clinics offering the service privately...
By Isabelle Bartram, Guest Contributor
| 03.13.2024
Note: This article was originally published in February 2024 in issue 268 of the German-language journal Der Gen-ethische Informationsdienst (GID). It is also part of an English-language dossier on Heritable Human Genome Editing published at the same time. Minor edits have been made.
Calls for German embryo research
Pressure on the German Embryo Protection Act is growing. The scientific community is launching a renewed attack on the controversial law and demands access to embryos for so-called high-ranking research objectives. "Germline therapies" are...
By Andrew Joseph, STAT | 02.22.2024
In the years leading up to Russia’s invasion, Ukraine had become a burgeoning hub of clinical trials, particularly in oncology. The war put a hold on the vast majority of those studies.
But as the country marks two years this...